Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy.

Genre F, López-Mejías R, Miranda-Filloy JA, Carnero-López B, Gómez-Acebo I, Blanco R, Ochoa R, Rueda J, González-Juanatey C, Llorca J, González-Gay MÁ.

Clin Exp Rheumatol. 2013 Nov-Dec;31(6):913-8.

PMID:
23981480
2.

Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.

Genre F, López-Mejías R, Miranda-Filloy JA, Carnero-López B, Gómez-Acebo I, Blanco R, Ochoa R, Rueda J, González-Juanatey C, Llorca J, González-Gay MA.

Clin Exp Rheumatol. 2013 Sep-Oct;31(5):749-55.

PMID:
23806325
3.

Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.

Miranda-Filloy JA, López-Mejias R, Genre F, Carnero-López B, Ochoa R, Diaz de Terán T, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.

Clin Exp Rheumatol. 2013 May-Jun;31(3):365-71.

PMID:
23294554
4.

Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.

Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Palmou-Fontana N, Gómez-Acebo I, Blanco R, Rueda-Gotor J, Pina T, González-Juanatey C, Llorca J, González-Gay MÁ.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5):640-6.

PMID:
25190453
5.

TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients.

Miranda-Filloy JA, Llorca J, Carnero-López B, González-Juanatey C, Blanco R, González-Gay MA.

Clin Exp Rheumatol. 2012 Nov-Dec;30(6):850-5.

PMID:
22765845
6.

Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.

Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Gómez-Acebo I, Blanco R, Ochoa R, Rueda-Gotor J, González-Juanatey C, Llorca J, González-Gay MA.

Clin Exp Rheumatol. 2014 Mar-Apr;32(2):218-24.

PMID:
24351434
7.

Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.

Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Gómez-Acebo I, Blanco R, Ochoa R, Arias-Bajo M, Rueda-Gotor J, Paz-Carreira J, González-Juanatey C, Llorca J, González-Gay MA.

Clin Exp Rheumatol. 2014 Mar-Apr;32(2):231-6.

PMID:
24295386
8.

Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.

Miranda-Filloy JA, López-Mejias R, Genre F, Carnero-López B, Ochoa R, Diaz de Terán T, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):538-45.

PMID:
23711190
9.

Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy.

Genre F, Miranda-Filloy JA, López-Mejias R, Carnero-López B, Ochoa R, Rueda J, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):532-7.

PMID:
23484462
10.

Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis.

Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, De Matias JM, Martin J, Dessein PH, Llorca J.

Clin Exp Rheumatol. 2008 Mar-Apr;26(2):311-6.

PMID:
18565254
11.

Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.

Genre F, López-Mejías R, Rueda-Gotor J, Miranda-Filloy JA, Ubilla B, Carnero-López B, Palmou-Fontana N, Gómez-Acebo I, Blanco R, Pina T, Ochoa R, González-Juanatey C, Llorca J, González-Gay MA.

Mediators Inflamm. 2014;2014:798060. doi: 10.1155/2014/798060.

12.

Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients.

Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Mijares V, Carnero-López B, Gómez-Acebo I, Dierssen-Sotos T, Remuzgo-Martínez S, Blanco R, Pina T, González-Juanatey C, Llorca J, González-Gay MA.

Rheumatol Int. 2015 Dec;35(12):2069-78. doi: 10.1007/s00296-015-3314-1.

PMID:
26143161
13.

[Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].

Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.

Zhonghua Yi Xue Za Zhi. 2006 Sep 19;86(35):2451-4. Chinese.

PMID:
17156669
14.

Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.

Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH, Llorca J.

Clin Exp Rheumatol. 2009 Mar-Apr;27(2):222-8.

PMID:
19473561
15.

Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, Berja A, Miranda-Filloy JA, de Matias JM, Gonzalez-Juanatey C, Llorca J.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1):56-62.

PMID:
20346239
16.

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.

Arthritis Rheum. 2009 Nov 15;61(11):1484-90. doi: 10.1002/art.24838.

17.

Relationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapy.

Pina T, Genre F, Lopez-Mejias R, Armesto S, Ubilla B, Mijares V, Dierssen-Sotos T, Gonzalez-Lopez MA, Gonzalez-Vela MC, Blanco R, Hernández JL, Llorca J, Gonzalez-Gay MA.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):1995-2001. doi: 10.1111/jdv.13131.

PMID:
25823684
18.

Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment.

Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN.

Clin Exp Rheumatol. 2010 Nov-Dec;28(6):880-3.

PMID:
21122270
19.

IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.

Genre F, López-Mejías R, Rueda-Gotor J, Miranda-Filloy JA, Ubilla B, Villar-Bonet A, Carnero-López B, Gómez-Acebo I, Blanco R, Pina T, González-Juanatey C, Llorca J, González-Gay MA.

Biomed Res Int. 2014;2014:671061. doi: 10.1155/2014/671061.

20.

Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis.

Bes C, Yazici A, Soy M.

Rheumatol Int. 2013 Jun;33(6):1415-8. doi: 10.1007/s00296-012-2539-5.

PMID:
23143665

Supplemental Content

Support Center